Skip to main content
Fig. 2 | Cost Effectiveness and Resource Allocation

Fig. 2

From: Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective

Fig. 2

Cost effective frontier: a secukinumab 150 mg, b secukinumab 300 mg, c secukinumab 300 mg. ADA, adalimumab; APR, apremilast; BS, biosimilar; CER P, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; PsA, Psoriatic arthritis; QALYs, quality adjusted life years; SEC, secukinumab; UST, ustekinumab

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us